Public Release: 

Synthetic molecule 'kicks and kills' some persistent HIV in mice

New compound shows early promise as potential treatment for dormant HIV infection

PLOS

IMAGE

IMAGE: A) Structure of bryostatin 1. B) Structure of bryostatin analog SUW133. view more 

Credit: Marsden MD, et al. (2017)

Scientists have designed a synthetic molecule that can reactivate dormant human immunodeficiency virus (HIV) in mice and lead to the death of some of the infected cells, according to a study published in PLOS Pathogens.

The new findings address a long-standing challenge in HIV treatment: While antiretroviral therapy can successfully stave off disease progression, the virus can silently persist in some cells for many years, so an infected person must be vigilantly treated for the rest of their life.

Previous studies have explored potential ways to eliminate latently infected cells, such as by stimulating them to produce some viral particles ("kick"), followed by cell death via the immune system or the virus itself ("kill"). A molecule called bryostatin 1 holds the potential to trigger a "kick and kill" response, but it is costly to obtain from its source, a marine animal known as Bugula neritina.

To address this challenge, Matthew Marsden and Jerome Zack of UCLA and Wender Group colleagues at Stanford have designed synthetic molecules capable of imitating the activity of bryostatin 1 and perhaps even improving on its function. In the new study, the team tested SUW133, one of their more promising synthetic bryostatin 1 analogs.

The researchers first demonstrated that SUW133, like bryostatin 1, is capable of activating latent HIV infection in cells removed from infected patients. Then, they tested SUW133 in mice of a strain commonly used for HIV research, in which the mouse immune system is modified to be similar to that of humans.

Molecular analysis revealed that SUW133 stimulated HIV protein production in latently infected cells in the mice. Within 24 hours, up to 25% of these cells then died. SUW133 was also better tolerated by the mice than was bryostatin 1.

These results support the potential for SUW133 to be used in a "kick and kill" treatment for HIV. Further research is needed to explore this potential and answer questions such as whether a greater percentage of cells could be killed over longer periods of time or with repeated dosing, whether similar effects might be seen in humans, and what the long-term effects of SUW133 may be.

###

In your coverage please use this URL to provide access to the freely available article in PLOS Pathogens: http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006575

Citation: Marsden MD, Loy BA, Wu X, Ramirez CM, Schrier AJ, Murray D, et al. (2017) In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication. PLoS Pathog 13(9): e1006575. https://doi.org/10.1371/journal.ppat.1006575

Funding: This work was supported by grants from the National Institute of Health ([https://www.nih.gov/] AI70010 and U19AI096113, project 3.4 to JAZ; CA31841 and CA31845 to PAW; AI124743 to JAZ and PAW; and AI124763 to MDM), a Bill and Melinda Gates Foundation Explorations grant ([http://www.gatesfoundation.org/] OPP1032668 to JAZ), the James B. Pendleton Charitable Trust, and the UCLA Center for AIDS Research (AI28697). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: I have read the journal's policy and the authors of the manuscript have the following competing interests: Neurotrope Biosciences and BryoLogyx have licensed some of this technology from Stanford University (P.A.W.), the former for the treatment of neurological disorders such as Alzheimer's disease and the latter for use in HIV/AIDS eradication and cancer immunotherapy. P.A.W is a consultant to both companies and a co-founder of BryoLogyx.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.